Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases

Spence, Ray A. J.; MacKenzie, Gilbert; Anderson, John R.; Lyons, Arnold R.; Bell, Millar

doi:10.1002/1097-0142(19850201)55:3<648::aid-cncr2820550329>3.0.co;2-3

Cited by 53 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was also reflected in a UK study comparing outcome in 41 MBC and 123 FBC which showed that when matched for key prognostic factors (size, grade and lymph node status), outcome was similar between genders [38], agreeing with our study. Of note was the observation that when MBC was compared with an unselected FBC group, males had worse outcome [38], which may explain some of the earlier studies inferring a worse prognosis in men [39,40]. Gender comparative information obtained from 1988 to 2003 SEER data showed worse breast cancer-specific survival in males diagnosed with stage I disease; however, the authors attributed this to in-stage migration rather than being of clinical relevance [41].…”

Section: Discussionmentioning

confidence: 99%

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Shaaban

Ball

Brannan

et al. 2011

Breast Cancer Res Treat

115

View full text Add to dashboard Cite

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phenotype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Shaaban

Ball

Brannan

et al. 2011

Breast Cancer Res Treat

115

View full text Add to dashboard Cite

show abstract

“…The retrospective data presented in this review suggests that adjuvant RT in MBC provides a LRC benefit, [34][35][36][37][40][41][42][43] as has been shown in women. Survival data in men are limited due to the small numbers and lack of long-term follow up.…”

Section: Discussionmentioning

confidence: 99%

“…34 A series from Ireland published in 1984 showed that men who underwent PMRT had longer mean time to LF (mean 2.9 years compared with 1.8 years). 35 In 1990, a review of 16 patients demonstrated no LF in patients who received adjuvant RT, but a 66.7 % LF rate in patients after surgery alone. 36 A large series from Milan showed significant reductions in LF, as low as 1.6 %, with PMRT and nodal radiation.…”

Section: Radiation Therapy In Male Breast Cancermentioning

confidence: 94%

Radiation Therapy in Male Breast Cancer

Bagshaw¹,

Cloyd²,

Poppe³

et al. 2013

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

Male breast cancer (MBC) is a relatively rare disease and because the dedicated literature on MBC is limited, management typically follows guidelines established for female breast cancer (FBC). Although radiation therapy (RT) comprises a critical role in the treatment of MBC, several unique challenges influence its use. Most men with breast cancer present at an older age with more extensive and advanced stage disease than women. In contrast to the predominance of breast conservation therapy in women with breast cancer, the majority of men are treated with mastectomy, with or without post-mastectomy radiation. Although no prospective or randomised trials are available, retrospective data suggests that surgery followed by adjuvant RT significantly improves locoregional control (LRC) in men. This article reviews the utilisation, efficacy and complications associated with adjuvant RT in MBC. KeywordsMale breast cancer, radiotherapy, adjuvant, outcomes, locoregional control, survival cancer that influence the role of adjuvant radiotherapy (RT). Men are not screened for breast cancer and commonly present at an older age and higher stage than women, and are more likely to present with a palpable mass that is centrally located.2,3 Due to the location and the low volume of normal breast tissue in men, there is a high propensity for nipple, chest wall and nodal involvement 3,4 resulting in more advanced stage at diagnosis and possibly greater need for post-mastectomy radiation (PMRT).2 Based on data from randomised clinical trials, adjuvant RT improves locoregional control (LRC) following lumpectomy and radiation in many circumstances. [5][6][7][8] In this article, we review the literature associated with the role of adjuvant RT in MBC. Role of Radiation Therapy in Locoregional Control Post-mastectomy RadiotherapyIn the US, PMRT has traditionally been indicated in women with four or more positive lymph nodes, T3 tumours or stage III disease.9,10 Multiple randomised trials have demonstrated improvement in LRC and overall survival (OS) with the addition of PMRT (see Table 1 Breast Conservation TherapyBreast conservation therapy (BCT) is defined as partial mastectomy (e.g. lumpectomy, segmentectomy, quandrectomy) followed by RT with or without adjuvant hormonal or systemic chemotherapy. Since the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 trial demonstrated equivalent survival outcomes among women with breast cancer undergoing radical mastectomy, total mastectomy with PMRT or simple mastectomy with axillary node dissection (ALND), there has been a shift to less extensive surgery.6 NSABP B-06 compared

show abstract

“…The 5-and 10-year overall survival rates in the present material were more favourable than some rates from the same period of time, reported by other authors (3,19,21). However, in contrast to these reports, cases with disseminated disease were not included in our material which might explain this difference.…”

Section: Discussionmentioning

confidence: 99%